Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Abstract

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) combination therapy has become the new standard of care in patients with unresectable hepatocellular carcinoma. However, potential predictive biomarkers and mechanisms of response and resistance remain less well understood. We report integrated molecular analyses of tumor samples from 358 patients with hepatocellular carcinoma (HCC) enrolled in the GO30140 phase 1b or IMbrave150 phase 3 trial and treated with atezolizumab combined with bevacizumab, atezolizumab alone or sorafenib (multikinase inhibitor). Pre-existing immunity (high expression of CD274, T-effector signature and intratumoral CD8 + T cell density) was associated with better clinical outcomes with the combination. Reduced clinical benefit was associated with high regulatory T cell (Treg) to effector T cell (Teff) ratio and expression of oncofetal genes (GPC3, AFP). Improved outcomes from the combination versus atezolizumab alone were associated with high expression of VEGF Receptor 2 (KDR), Tregs and myeloid inflammation signatures. These findings were further validated by analyses of paired pre- and post-treatment biopsies, in situ analyses and in vivo mouse models. Our study identified key molecular correlates of the combination therapy and highlighted that anti-VEGF might synergize with anti-PD-L1 by targeting angiogenesis, Treg proliferation and myeloid cell inflammation.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01868-2

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 59 references

Cited by

See all 729

Metadata

Authors
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., Yau, T., Kaseb, A. O., Burgoyne, A. M., Dayyani, F., Spahn, J., Verret, W., Finn, R. S., Toh, H. C., Lujambio, A., & Wang, Y.
Affiliations
  • Harvard University (US)
  • Genentech (US)
  • National Taiwan University Hospital (TW)
  • Georgetown University Medical Center (US)
  • Asan Medical Center (KR)
  • University of Hong Kong (HK)
  • The University of Texas MD Anderson Cancer Center (US)
  • Moores Cancer Center (US)
  • UC Irvine Health (US)
  • University of California, Los Angeles (US)
  • National Cancer Centre Singapore (SG)
  • Tisch Cancer Institute (US)
Corresponding author
Wang, Yulei
Venue
Nature Medicine
Published
2022-06-23
Volume
28
Issue
8
Pages
1599-1611
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4283325186
Cited by
652
References
59
Citations by year
2026: 136 · 2025: 176 · 2024: 180 · 2023: 129 · 2022: 30
FWCI
76.85
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders
National Cancer Institute (R37CA230636, P30CA051008, P30CA196521)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
hepatocellular carcinoma, atezolizumab, bevacizumab, PD-L1, vascular endothelial growth factor, combination immunotherapy, predictive biomarkers, treatment resistance, regulatory T cells, tumor-infiltrating CD8+ T cells, oncofetal genes, glypican-3, alpha-fetoprotein, KDR, myeloid inflammation, tumor immune microenvironment, sorafenib, multi-omics
MeSH terms
Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Inflammation, Liver Neoplasms, Clinical Trials, Phase I as Topic, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41591-022-01868-2
The paper
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., Yau, T., Kaseb, A. O., Burgoyne, A. M., Dayyani, F., Spahn, J., Verret, W., Finn, R. S., Toh, H. C., Lujambio, A., & Wang, Y. (2022). Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-022-01868-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.